Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide.
Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide.
复制标题
DOI：
10.1097/mib.0b013e3182a8452e
复制
发表时间：
2013-12
影响因子：
4.9
通讯作者：
Kuemmerle JF
中科院分区：
文献类型：
--
作者：
Li C;Flynn RS;Grider JR;Murthy KS;Kellum JM;Akbari H;Kuemmerle JF
Strictures develop in >30% of Crohn’s disease. No available medication prevents stricture development in susceptible patients. In Crohn’s strictures, but not adjacent normal intestine, TGF-β1 increases in muscularis smooth muscle, increasing collagen I production and strictures. Muscle cells express αVβ3 integrin containing an RGD binding domain. The aim was to determine whether increased TGF-β1 levels in strictures was the result of latent TGF-β1, which contains an RGD sequence , binding to and activation by αVβ3; and whether cilengitide, which is an RGD-containing αVβ3 integrin inhibitor, decreases TGF-β1 activation and development of fibrosis in chronic TNBS-induced colitis Muscle cells were isolated from Crohn’s disease strictures and normal resection margin and from colon of rats after 42 d of chronic TNBS-induced colitis were used to prepare RNA, protein lysates and initiate primary cultures. The mechanisms leading to increased TGF-β1 activation, collagen I production and fibrosis were examined in human muscle and in rats. Human cultured cells in vitro and rats in vivo were treated with cilengitide to determine it efficacy to decrease TGF-β1-activation, collagen production and decrease the development of fibrosis. Latent TGF-β1 is activated by the αVβ3 RGD domain in human and rat intestinal smooth muscle. Increased activation of TGF-β1 in Crohn’s disease and in TNBS-induced colitis causes increased collagen production, and fibrosis that could be inhibited by cilengitide. Cilengitide, a αVβ3 integrin RGD inhibitor, could be a novel treatment to diminish excess TGF-β1 activation, collagen I production and development of fibrosis in Crohn’s disease.
